Workflow
Lonza(LZAGY) - 2021 Q2 - Earnings Call Presentation
LonzaLonza(US:LZAGY)2021-07-23 15:45

Financial Performance - Lonza achieved strong performance with sales growth of 14.7% CER and a CORE EBITDA margin of 33.3% despite COVID-19 headwinds[5] - H1 2021 sales reached CHF 2542 million, reflecting a 14.7% increase CER[18] - CORE EBITDA for H1 2021 was CHF 847 million, a 14.8% increase CER[18] - The company's ROIC was 11.5%, a 0.7 percentage points increase[36] Strategic Initiatives - Lonza completed the divestment of its Specialty Ingredients business to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion[6] - The company is investing heavily in internal growth projects, with 80% of H1 CAPEX of CHF 474 million allocated to support future growth[8] - An initial provision of CHF 290 million has been made for the first phase of remediation at the Gamsenried landfill site[15] Divisional Performance - Biologics division experienced sales growth of 16.7% CER with a CORE EBITDA margin of 38.2%[23] - Small Molecules division saw sales growth of 16.5% CER and a CORE EBITDA margin of 27.3%[23] - Cell & Gene division achieved sales growth of 24.7% CER with a CORE EBITDA margin of 16.1%[23] - Capsules & Health Ingredients (CHI) division had sales growth of 5.8% CER with a CORE EBITDA margin of 35.4%[23] Outlook - Lonza revised its 2021 outlook upwards to mid-teens CER sales growth[5, 69]